tirzepatide and psoriatic arthritis Taltz plus promising in arthritis, obesity Tirzepatide Added to Ixekizumab Improves

A physician must determine whether the patient fits the appropriate medical criteria and how GLP-1 therapy should fit into the larger care plan

Reassuringly, only a very small percentage of people with T2D experienced hypoglycaemia in the phase 2 trial which included people on lifestyle interventions or metformin

Clinical trials such as the STEP programme (semaglutide) and SUSTAIN studies show that: Initial weeks : Modest weight loss primarily from reduced caloric intake Months 23 : More noticeable reduction becomes evident Months 36 : Continued steady weight loss as dose escalates Months 612 : Peak weight loss approaches, with most studies showing maximal effect by 1218 months It is important to recognise that GLP-1 medications require dose titration starting at a low dose and gradually increasing over several weeks according to the specific product's SmPC

Responsible use of this medication is key, and our team is able to safely monitor this medication as part of our protocol says Dr